Neurotoxicity After CAR-T — Confusion and Speech Problems

It usually starts small. A hesitation finding ordinary words. Handwriting that has gone shaky or shrunk. Not knowing the date, or which hospital this is. Confusion, heavy drowsiness, slurred speech or a seizure can follow. Tell the ward nurse the moment you notice any of it, however small it seems.

Say it now, not at the next ward round. If the person is admitted, tell the nurse or the on-call cell-therapy team immediately — at 3am, on a Sunday, for a change you are not sure about. Families notice this before the staff do, because you know how the person normally speaks. If you are already home after discharge and cannot reach the treating centre, go to the nearest emergency department and say the words “this person had CAR-T cell therapy on” with the date. That sentence changes how quickly they are seen. There is no home treatment for this, and nothing on this page is a reason to wait and watch. CION’s helpline, 1800 202 8726, can help you make sense of it afterwards, but CION is not the treating team and does not provide CAR-T.

It has a name. Doctors call it ICANS — immune effector cell-associated neurotoxicity syndrome. It is a known, expected, monitored complication of CAR-T cell therapy. It is not a stroke, not dementia, and not the person “being difficult”. It happens because the treatment sets off a large immune reaction, and the brain is sensitive to that reaction. Every accredited centre screens for it several times a day for exactly this reason.

It often follows the fever. Cytokine release syndrome — high fever, low blood pressure, feeling wretched — usually comes first, in the first few days. Neurological effects tend to arrive after it or alongside it. A person can also have one without the other. The team watches for both from the day of infusion.

Said plainly, before anything else: CION Cancer Clinics does not provide CAR-T cell therapy or any other cell therapy. We do not administer it, stock it or manufacture it, and we quote no price for it. This page exists because families sitting beside a patient in an accredited centre are often handed a word like ICANS with no explanation of what it will look like or how long it lasts. Immunotherapy at CION means checkpoint-inhibitor treatment given as day care, which is a different class of treatment with a different side-effect pattern.

Most often in the first week to ten days after the infusion, commonly after or alongside the fever of cytokine release syndrome. In the majority of reported cases it settles within about a week or two once treated. A smaller proportion is severe or takes longer. Windows are indicative, as of August 2026.

Why the timing is the whole reason for the accredited-centre rule. The window in which this appears is the window in which the patient must be within minutes of a team that recognises it. That is why centres ask families to stay in the same city for weeks, why discharge is not on day three, and why cell therapy is delivered only at a handful of accredited units in India. The inconvenience is the safety feature.

In most patients, yes. The pattern reported in trials and in guideline summaries is that these effects resolve over days once treated, and speech and thinking return to normal. A minority become severe and need intensive care. A small number have effects that last longer. No one can promise an outcome for one person.

What “reversible” does and does not mean. It means the syndrome itself is expected to settle, not that the person walks out unchanged the next morning. Families frequently describe a lag: the confusion clears first, then tiredness and word-finding take longer, sometimes weeks. That lag is common and is not, by itself, a sign that something has been missed. It is still worth reporting at every follow-up so that it is documented.

Where honesty is required. Severe neurological events after cell therapy do happen, including rare life-threatening ones, and long-term neurological outcomes are still being collected worldwide. Any page telling you this is always temporary is overstating what is known. Ask the treating haemato-oncologist which grading is being used, what grade this patient is at today, and what the plan is if it worsens tonight.

The ten-point check the ward is doing

Most accredited centres score neurotoxicity with a short bedside test, several times a day. Knowing what is being asked stops it feeling like an interrogation, and lets you report changes in the same language the team uses.

• Orientation — year, month, city, hospital. Four points.
• Naming — name three objects the examiner points to. Three points.
• Following commands — a simple instruction, such as showing two fingers. One point.
• Writing — write one standard sentence. One point.
• Attention — count backwards from 100 by tens. One point.

Ask for the number. “What was the score at the last check, and what was it four hours before that?” is a better question than “is he alright?”, and it gets a better answer. Write the numbers down with the time. If the family is doing shifts at the bedside, hand the sheet over with the shift.

Because the treatment deliberately provokes a very large immune reaction, and the brain is sensitive to it. Immune messenger chemicals rise sharply, the lining of small blood vessels becomes leaky, and brain function is disturbed. The reprogrammed cells are not attacking the brain itself. The mechanism is still not fully settled.

What is reasonably well accepted. The reprogrammed cells multiply rapidly after infusion and release a surge of inflammatory signals. Those signals affect the blood-vessel lining, including the barrier that normally protects the brain. Inflammation reaches tissue it does not usually reach, and the result is disturbed thinking, speech and, in severe cases, seizures. This is why neurological effects so often follow the fever phase.

What is not settled. Why one patient develops severe effects while another with the same disease develops none is not fully explained. Risk is generally described as higher with a large disease burden and a more intense fever phase, but there is no reliable way to predict it in an individual before the infusion. Say that plainly back to anyone who gives you an assurance that sounds too specific.

What it is not. It is not a psychiatric illness, not a reaction to being in a strange ward, not simple sleep deprivation, and not the person’s character changing. It is a physical, treatable, monitored complication of the treatment. Families who are told “he is just tired” and feel that something else is wrong are usually right to push.

Entirely in hospital, by the cell-therapy team. There is no home remedy and no waiting it out. Treatment is graded: closer monitoring at the mild end, anti-inflammatory medicines and specialist input in the middle, critical care at the severe end. None of it is something a family should attempt on their own.

1. 1

   Scored, repeatedly, from the day of infusion

   The bedside score is done several times a day, and more often if anything changes. This is not fuss. Catching a two-point drop early is the difference between a mild course and a severe one, and it is the reason the patient is kept close to the unit.

2. 2

   Other causes ruled out first

   Infection, low sodium, low blood sugar, kidney or liver problems, sedating medicines and lack of sleep can all cloud thinking. The team checks bloods, and often images the brain, precisely so a treatable second cause is not missed while everyone assumes it is the cell therapy.

3. 3

   Anti-inflammatory treatment, graded to severity

   Corticosteroids are the mainstay for neurological effects, given and then tapered on the centre’s protocol. Where a fever reaction is present as well, the team may add a targeted antibody that blocks the relevant immune signal. Doses, timing and choices are the treating centre’s decision and vary by grade and by unit.

4. 4

   Seizure prevention and neurology input

   Many units give a preventive anti-seizure medicine through this period as routine, and involve a neurologist as the grade rises. Brain imaging and, sometimes, a brain-wave test are used to check for silent seizure activity in someone who is drowsy or not responding normally.

5. 5

   Critical care at the severe end

   Severe cases are managed in intensive care, where the airway, seizures and pressure inside the skull can be handled properly. An intensive-care stay lengthens the admission and adds to what the family pays. Any cost figure in this pathway is indicative only, as of August 2026, and must be confirmed in writing with the treating centre.

More than you think, and none of it is medical. You are the baseline. The staff met this person a week ago. You have known them for decades, and you will notice the change first.

• Keep the daily handwriting sheet — same sentence, same pen, dated, kept in order so the change is visible rather than remembered.
• Report the specific thing, not the impression — “he could not name the watch and said it was Tuesday” is far more useful than “he seems off”.
• Write down the score and the time — and hand the sheet over when the next family member takes the shift, so nothing is lost between visitors.
• Do not cover for them — finishing their sentences, answering for them or laughing off a wrong date hides the exact signal the team is looking for.
• Look after your own sleep — this is a marathon of weeks, and two people rotating badly is worse than two people rotating on a plan.

Ask these before the infusion if you still can, and during the admission if you did not. Every one of them has a clear answer at a centre that does this often.

• What grading do you use, and can we see the score each day? A unit that shares the number is a unit measuring it properly.
• How long must we stay within reach of this centre, in writing? Distance and duration decide accommodation, leave from work and cost.
• Who do we call at 2am, and what number reaches a person rather than a switchboard? Save it in two phones before you need it.
• If it becomes severe, is intensive care in this same building? A transfer between hospitals mid-event is not what you want to discover then.
• Who manages follow-up if we live in another state? Get the local arrangement agreed before discharge, not after.

No. CION Cancer Clinics does not administer, stock or manufacture CAR-T or any other cell therapy, and quotes no price for it. This page is orientation and referral guidance only, written for families already inside that pathway or being asked to consider it.

What we can do is read the reports and give a straight answer: whether this diagnosis sits in a category where cell therapy is genuinely discussed, what the pathway and its weeks of close monitoring would realistically ask of your family, and what the treatment already offered is worth as a written second opinion. Where referral to an accredited cell-therapy centre is the right next step, we will say so and help you prepare the record.

The immunotherapy given as day care at CION centres is checkpoint-inhibitor treatment — a different class, with a different schedule and a different side-effect pattern, though it has its own immune-related effects that need the same early reporting. Response-assessment PET-CT during that treatment is coordinated at partner imaging centres rather than owned by CION. The first consultation is free, takes 45 minutes, and carries no commitment to start treatment anywhere.

• The Hospital Stay for CAR-T: How Long and What Happens — the admission this page sits inside, day by day, and why the family has to stay within reach of the centre for weeks.
• Life After CAR-T: Recovery, Immunity and Follow-Up — what happens after the confusion clears: rebuilding immunity, revaccination, driving, work, and follow-up counted in years.
• CAR-T vs Stem Cell Transplant: Which and When? — the comparison most families are actually weighing, including how the two differ in risk, length of stay and eligibility.
• Immunotherapy at CION Cancer Clinics — the treatments CION does provide, how eligibility is assessed, and what a free first consultation covers.

This page is general information for families and does not replace the treating team. CION Cancer Clinics does not provide CAR-T or any cell therapy; immunotherapy at CION means checkpoint-inhibitor treatment given as day care, with response-assessment PET-CT coordinated at partner imaging centres. No product or brand is named on this page. Timings, score bands and management descriptions are indicative, as of August 2026, drawn from patterns reported in trial populations and summarised in NCCN, ASCO and ESMO guidance on immune-effector-cell toxicity, and are not predictions for any individual. Long-term neurological data after gene-modified cell therapy is still maturing. Any new confusion, speech change, drowsiness or seizure is an emergency for the treating centre, not something to manage at home.

Most families reach this page from a bedside, mid-shift, with a phone in one hand

Ask us what you are seeing and what it usually means. You will get a plain answer, including when the answer is that this belongs entirely to the treating centre.